37
Participants
Start Date
January 15, 2020
Primary Completion Date
December 23, 2026
Study Completion Date
December 23, 2026
CHO-H01
"Phase 1:~Subjects will be administered intravenous (IV) infusion of assigned dose level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 21-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
CHO-H01 at RP2D
"Subjects will be administered intravenous (IV) infusion of RP2D level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 28-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
Lenalidomide
Subjects will receive oral lenalidomide 20 mg once daily from Day 1 to Day 21 per 28-day cycle.
RECRUITING
National Taiwan University Hospital - Hematology And Oncology, Taipei
RECRUITING
China Medical University Hospital - Hematology/Oncology - Taichung, Taichung
RECRUITING
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung City
RECRUITING
Tri-Service General Hospital - Neihu Branch - Hematology, Taipei
RECRUITING
Taipei Medical University - Shuang Ho Hospital - Oncology, New Taipei City
TERMINATED
Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology, Taoyuan District
RECRUITING
National Cheng Kung University Hospital - Internal Medicine, Tainan City
WITHDRAWN
Renovatio Clinical, The Woodlands
Lead Sponsor
Cho Pharma Inc.
INDUSTRY